SLIDE 8 Sixmonthsafterdiagnosisandinitiationof treatment,thesurvivalrateswere95%forthe Neuroxomabgroup,91%fortheBlasteride group,and39%fortheradiationtreatedgroup (Fig.1).At12monthstherateswere83%,69%, and23%;at18months74%,17%,and15%; andat24months70%,11%,and9%.
Thisparagraphprovidesdatabutnoresults: Whatdothedatashow? Whatisthepoint? Arethetreatmentgroupsdifferentat6months?
Sixmonthsafterdiagnosisandinitiationof treatment,thesurvivalrateswerehigherin theNeuroxomabandBlasteridetreatment groupsthanintheradiationtreatmentgroup (Fig.1).At12,18,and24monthsthesurvival ratesintheNeuroxomabgroupexceeded thoseofboththeBlasterideandradiation treatmentgroups.
Thisparagraphcontainsminimalexplanationofwhatthedata show: HowmuchhigherwerethesurvivalratesfortheNeuroxomab andBlasteride groupsthantheradiationgrouporeachother?
Sixmonthsafterdiagnosisandinitiationoftreatment, the survivalratesfortheNeuroxomabandBlasteride groupswere 2.4and2.3timeshigher,respectively, thantheradiationtreatment group(bothP<0.001), butsurvivalratesdidnotdifferbetweenthe NeuroxomabandBlasteridegroups(P= 0.56)(Fig.1). By12months,however,patientsurvivalin the Neuroxomabgroupwas1.2timeshigherthaninthe Blasteride group(P=0.031),and4.3and6.4times higherat18and24 months(bothP<0.001).
Thisparagraphexplainswhatthedatashow: Themagnitude(e.g.,2.4timeshigher)ofthemost importantdifferences Whenthedifferencesoccurred Whethertheywerestatisticallysignificant
Sixmonthsafterdiagnosisandinitiationoftreatment, survivalratesintheNeuroxomabandBlasteridegroups (95%and91%,respectively)were2.4and2.3times higherthanthesurvivalratefortheradiation treatment group(bothP<0.001),butsurvivalratesdid notdifferbetweentheNeuroxomabandBlasteride groups(P=0.56)(Fig.1).By12months,however,the patientsurvivalrateintheNeuroxomabgroupwas1.2 timeshigherthanintheBlasteridegroup(83%vs69%, P=0.031),adifferencethatbecameevengreaterat18 and24months(74%vs17%and70%vs11%;bothP< 0.001).
Thisparagraphexplainswhatthedatashowandprovidessome importantdatafromthefigure: Includestheactualsurvivalrates(e.g.,95%,91%,and39%at6 months)inadditionthemagnitudeofanydifferences. Table1.Patientsurvivalratesafter3differenttreatmentregimens.
Survival,%
__________________________________________________________________________________________
Time,months Neuroxomab Blasteride Radiation 6 951,2 911 39 12 831,3 691 23 18 741,4 17 15 24 701,4 11 9
Themaintextdescribestheresults,butdoesnotduplicatethedata: Sixmonthsafterdiagnosisandinitiationoftreatment,thesurvivalratesforthe Neuroxomab andBlasteride treatmentgroupswere2.4and2.3timeshigher thanfortheradiationtreatment group,butsurvivalratesdidnotdifferbetween theNeuroxomab andBlasteride groups(P=0.56)(Table1).By12months, however,patientsurvivalintheNeuroxomab groupwas1.2timeshigherthanin theBlasteride group,adifferencethatbecameevengreaterat18and24 months.
1 P<0.001vsradiationgroup.2P=0.56vsBlasteride.3 P=0.031vsBlasteride.4 P<0.001vsBlasteride.
Dataintablesshouldnotberepeatedinthe maintext.
Oneexception: Ifatablesuppliesaverylargeamountofdata,itis acceptabletorestateakeypieceofdatainthetext,suchas the2groupsinthetablewithstatisticallysignificant differences. Onlydothisifithelpsthereaderzeroinonanimportant resultwithouthavingtoplowthroughalonglistofdata.
